tiprankstipranks
MediWound’s NexoBrid Triumphs in Burn Care Study
Company Announcements

MediWound’s NexoBrid Triumphs in Burn Care Study

Mediwound (MDWD) has released an update.

Pick the best stocks and maximize your portfolio:

MediWound Ltd. reported positive outcomes from the NEXT protocol, showcasing the safety and effectiveness of their NexoBrid product in removing eschar and substantially reducing surgical procedures for burn patients. The program has verified NexoBrid’s rapid debridement capability in both adults and children, with the vast majority achieving complete eschar removal without the need for surgical excision. These results support NexoBrid’s integration into standard burn care protocols.

For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement
TheFlyMediWound to host virtual KOL event to discuss EscharEx Phase III VALUE study
TipRanks Auto-Generated NewsdeskMediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App